Department of Pharmaceutical Sciences, University of Tennessee Health Sciences Center, 19 South Manassas St., Memphis, Tennessee 38103, USA.
Pharm Res. 2012 Nov;29(11):3064-74. doi: 10.1007/s11095-012-0881-7. Epub 2012 Sep 28.
Since our newly synthesized potent 5-indolyl derivative, (2-(1 H-Indol-5-yl) thiazol-4-yl) 3, 4, 5-trimethoxyphenyl methanone (LY293), to treat resistant melanoma was hydrophobic, our objective was to synthesize a biodegradable copolymer for formulating this drug into nanoparticles and to determine its anticancer activity and mechanism of action.
Methoxy poly (ethylene glycol)-b-poly (carbonate-co-lactide) [mPEG-b-P (CB-co-LA)] was synthesized for formulating LY293 into nanoparticles by o/w emulsification and stabilization by solvent evaporation. Particle size, drug release profile, in vitro efficacy in multiple melanoma cells, and mechanism of action of drug-loaded nanoparticles were determined.
LY293-loaded nanoparticles with 170 nm mean size and 2.2 and 4.16% drug loading efficiently inhibited proliferation of A375 and B16F10 cells with IC(50) of 12.5 nM and 25 nM, respectively. LY293 circumvented multidrug resistance and inhibited proliferation of Pgp overexpressing MDA-MB435/LCC6 MDR1 melanoma cells. Upon treatment with LY293-loaded nanoparticles, A375 cells underwent cell cycle arrest in G2/M phase and apoptotic cell death. Immunofluorescence images showed inhibition of tubulin polymerization after treatment with LY293.
LY293-loaded mPEG-b-P (CB-co-LA) nanoparticles showed excellent efficacy and induced apoptosis in melanoma cells. These polyester/polycarbonate-based nanoparticles provided an excellent platform to deliver different poorly soluble drugs to melanoma.
由于我们新合成的强效 5-吲哚基衍生物,(2-(1H-吲哚-5-基)噻唑-4-基)3,4,5-三甲氧基苯基甲酮(LY293),用于治疗耐药性黑色素瘤,我们的目标是合成一种可生物降解的共聚物,将这种药物制成纳米粒,并确定其抗癌活性和作用机制。
合成甲氧基聚乙二醇-b-聚(碳酸酯-co-乳酸)[mPEG-b-P(CB-co-LA)],通过 o/w 乳化和溶剂蒸发稳定化,将 LY293 制成纳米粒。测定载药纳米粒的粒径、药物释放曲线、在多种黑色素瘤细胞中的体外疗效和作用机制。
平均粒径为 170nm、载药量分别为 2.2%和 4.16%的 LY293 载药纳米粒能有效抑制 A375 和 B16F10 细胞的增殖,IC50 分别为 12.5nm 和 25nm。LY293 可规避多药耐药并抑制 Pgp 过表达的 MDA-MB435/LCC6 MDR1 黑色素瘤细胞的增殖。LY293 载药纳米粒处理后,A375 细胞周期阻滞在 G2/M 期,并发生凋亡性细胞死亡。免疫荧光图像显示 LY293 处理后微管蛋白聚合受到抑制。
LY293 载 mPEG-b-P(CB-co-LA)纳米粒在黑色素瘤细胞中显示出优异的疗效和诱导凋亡作用。这些聚酯/聚碳酸酯基纳米粒为输送不同疏水性药物到黑色素瘤提供了一个极好的平台。